Provided by Tiger Trade Technology Pte. Ltd.

Salarius Pharmaceuticals Inc

0.8400
0.0000
Volume:- -
Turnover:- -
Market Cap:5.36M
PE:-0.02
High:0.8400
Open:0.8400
Low:0.8400
Close:0.8400
52wk High:108.00
52wk Low:0.5148
Shares:6.38M
Float Shares:6.34M
Volume Ratio:- -
T/O Rate:- -
Dividend:- -
Dividend Rate:- -
EPS(TTM):-39.1909
EPS(LYR):-86.9214
ROE:-139.55%
ROA:-69.91%
PB:1.26
PE(LYR):-0.01

Loading ...

BRIEF-Salarius Pharmaceuticals Changes Name To Decoy Therapeutics

Reuters
·
Jan 07

Salarius Pharmaceuticals Inc - Changes Name to Decoy Therapeutics

THOMSON REUTERS
·
Jan 07

Salarius Pharmaceuticals Inc - Trading Under Dcoy to Commence on January 8, 2026

THOMSON REUTERS
·
Jan 07

Salarius Pharmaceuticals Rebrands as Decoy Therapeutics

Reuters
·
Jan 07

Top Midday Decliners

MT Newswires Live
·
Jan 06

Nasdaq Moves to Delist Salarius Pharmaceuticals Over Minimum Bid Price Violation

Reuters
·
Jan 03

Director Arnold C. Hanish Reports Disposal of Salarius Pharmaceuticals Inc. Common Shares

Reuters
·
Jan 03

Salarius Pharmaceuticals Inc. held annual shareholder meeting

Reuters
·
Jan 03

Press Release: Salarius Pharmaceuticals Announces Adjournment of Annual Meeting, Information for Reconvened Annual Meeting

Dow Jones
·
Dec 20, 2025

Salarius Pharmaceuticals Rebrands as Decoy Therapeutics

Reuters
·
Dec 18, 2025

Salarius Pharmaceuticals Announces Planned Corporate Name and Ticker Symbol Change to Decoy Therapeutics, Reflecting Strategic Pivot to Next-Generation Antiviral and Peptide-Conjugate Platform

THOMSON REUTERS
·
Dec 18, 2025

Salarius Pharmaceuticals' Decoy Unit Partners With Texas Biomed on Flu Inhibitor Testing

MT Newswires Live
·
Dec 01, 2025

BRIEF-Salarius Pharmaceuticals To Collaborate With Texas Biomedical Research Institute On Avian Flu Study

Reuters
·
Dec 01, 2025

Salarius Pharmaceuticals to Collaborate With Texas Biomedical Research Institute on Avian Flu Study

THOMSON REUTERS
·
Dec 01, 2025

Salarius Pharmaceuticals Director Arnold C. Hanish Reports Acquisition of Common Shares

Reuters
·
Nov 25, 2025

Salarius Pharmaceuticals Files Initial Beneficial Ownership Statement for CEO Frederick II Pierce

Reuters
·
Nov 25, 2025

Salarius Pharmaceuticals CFO Mark J. Rosenblum Acquires Common Shares

Reuters
·
Nov 21, 2025

BRIEF-Salarius Pharmaceuticals Inc - Frederick E. Pierce To Serve As Chief Executive Officer - Filing

Reuters
·
Nov 20, 2025

Salarius Pharmaceuticals Inc - Frederick E. Pierce to Serve as Chief Executive Officer - Filing

THOMSON REUTERS
·
Nov 20, 2025

Salarius Pharmaceuticals Completes Merger With Decoy Therapeutics and Raises $8 Million

Reuters
·
Nov 20, 2025